This list contains references from the content that can be linked to their source. For a full set of references and notes please see the PDF or HTML where available.
1991Cardiovascular disease risk profiles.
Am Heart J.121:
1951Epidemiological approaches to heart disease: The Framingham Study.
Am J Public Health.41:
1993Standardizing methodologies for economic evaluation in health care. Practice, problems, and potential.
Int J Technol Assess Health Care.9:
2005Cost effectiveness of statins in coronary heart disease.
J Epidemiol Community Health.59:
2002Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the U.S. Preventive Services Task Force.
Ann Intern Med.136:
1997Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials.
van den OuwelandFA.
1991Determinants of disease and disability in the elderly: The Rotterdam Elderly Study.
Eur J Epidemiol.7:
2001Clinical context: Current concepts of coronary heart disease management.
Am J Med.110(Suppl 6A):
1979An investigation of coronary heart disease in families. The Framingham offspring study.
Am J Epidemiol.110:
2001Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
1999Effect of statins on risk of coronary disease: A meta-analysis of randomized controlled trials.
2002Risk factor thresholds: Their existence under scrutiny.
1997Short-term economic and health benefits of smoking cessation: Myocardial infarction and stroke.
2001Cost effectiveness of ramipril treatment for cardiovascular risk reduction.
2003Coronary heart disease prevention: Insights from modelling incremental cost effectiveness.
2004Economics of smoking cessation.
1996Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: Life table method applied to health authority population.
FordI, et al.
1995Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.
N Engl J Med.333:
2001Cost-effectiveness of HMG coenzyme reductase inhibitors; whom to treat?
Eur Heart J.22:
2003A strategy to reduce cardiovascular disease by more than 80%.
2002Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events.
Arch Intern Med.162: